ALLIGATOR BIOSCIENCE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0727 EUR | +0.69% |
|
+18.79% | +28.45% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +28.45% | 6.29Cr | - | ||
| +33.63% | 5.09TCr | B- | ||
| -0.09% | 4.21TCr | B | ||
| +49.62% | 4.2TCr | A | ||
| -4.96% | 2.92TCr | C | ||
| +11.18% | 2.6TCr | B- | ||
| -21.95% | 1.89TCr | B | ||
| +8.61% | 1.32TCr | B+ | ||
| +24.73% | 1.22TCr | B+ | ||
| +28.31% | 1.22TCr | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ATORX Stock
- 7AL Stock
- Ratings Alligator Bioscience AB
